Introduction
============

Bladder cancer is one of the most common health problems worldwide, the seventh most common malignancy in men, and 17th most common in women.[@b1-ott-9-579] It is well-known that the most common risk factors for bladder cancer include tobacco smoking,[@b2-ott-9-579] occupational exposure to chemicals,[@b3-ott-9-579] and schistosomiasis.[@b1-ott-9-579] Whereas, epidemiological studies have shown that genetic variants at one or more loci result in reduced DNA repair capacity and an increased cancer risk.[@b4-ott-9-579]--[@b6-ott-9-579] In addition, a large number of single nucleotide polymorphisms in common DNA repair genes have also been identified[@b7-ott-9-579] and confirmed to be associated with several sporadic cancers.[@b8-ott-9-579],[@b9-ott-9-579]

XRCC1 is located on chromosome 19q13.2--13.3[@b10-ott-9-579],[@b11-ott-9-579] with a length of 33 kb, and plays an essential role in DNA repair genes involved in base excision repair[@b12-ott-9-579] and single-strand breaks.[@b13-ott-9-579] To date, XRCC1 is the first cloned human gene associated with single-strand break repair[@b14-ott-9-579] and also related to sister-chromatid exchange.[@b15-ott-9-579] As previously described, there are three single nucleotide polymorphisms leads to amino acid substitutions in Arg194Trp in exon 6 (rs1799782), Arg280His in exon 9 (rs25489), and Arg399Gln in exon 10 (rs25487).[@b16-ott-9-579],[@b17-ott-9-579]

Although several previous studies have evaluated the associations of XRCC1 polymorphisms with bladder cancer risk, the results are still inconsistent. In the present study, we performed a meta-analysis of all eligible studies to demonstrate the effect of XRCC1 Arg399Gln polymorphism on bladder cancer susceptibility.

Materials and methods
=====================

Identification of eligible studies
----------------------------------

PubMed, Embase, and Web of Science databases were searched in our meta-analysis. Case-control studies of the XRCC1 Arg399Gln polymorphism and bladder cancer susceptibility published before June 1, 2015 were included by using the keywords: "XRCC1", "X-ray repair cross-complementing group 1", "Arg399Gln", "polymorphism", "bladder cancer", and "urothelial carcinoma". The search was limited to English language papers. All reference lists of reviews and retrieved articles were manually screened for further potential studies.

Inclusion and exclusion criteria
--------------------------------

The following criteria were used to determine inclusion eligibility: 1) a study that evaluated the correlation of XRCC1 Arg399Gln polymorphisms with bladder cancer susceptibility; 2) case-control study design; 3) full-text published articles; 4) a study that included sufficient genotype data for extraction. Furthermore, articles that did not meet our inclusion criteria were excluded.

Data extraction
---------------

Information was extracted carefully from all eligible publications independently and in duplicate by two authors. The following data were collected from each study: the first author's name, year of publication, country of origin, genotyping method, numbers of cases and controls, and evidence of Hardy-Weinberg equilibrium (HWE). The two authors reached consensus on each item.

Statistical analysis
--------------------

The strength of association between the XRCC1 Arg399Gln polymorphism and bladder cancer was calculated by individual or pooled odds ratios (ORs) and 95% confidence intervals (CIs) using the STATA statistical software (Version 12.0, StataCorp LP, College Station, TX, USA). We evaluated the following comparisons to the XRCC1 Arg399Gln polymorphism including comparison of the variant allele with the wild-type allele (Gln allele vs Arg allele), the variant homozygote with the wild-type homozygote and the heterozygote (Gln/Gln vs Gln/Arg + Arg/Arg), the wild-type homozygote with the variant homozygote and the heterozygote (Arg/Arg vs Gln/Arg + Gln/Gln), and the variant homozygote with the heterozygote and wild-type homozygote (Gln/Gln vs Arg/Arg; Gln/Gln vs Gln/Arg). The statistical significance of the pooled ORs was assessed with the Z test and a *P*-value of \<0.05 was considered significant. Chi-square-based Q test was conducted to measure the heterogeneity between eligible studies, and the existence of heterogeneity was considered significant if *P*\<0.10.[@b11-ott-9-579] When the between-study heterogeneity was absent, a fixed-effect model (the Mantel--Haenszel method) was used to pool the data from different studies.[@b18-ott-9-579] Otherwise, a random-effect model (the DerSimonian and Laird method) was applied.[@b19-ott-9-579] To explore the source of heterogeneity among variables such as ethnicity, and HWE status, both subgroup analyses and logistic met regression analyses were performed.[@b20-ott-9-579] Funnel plots and Egger's linear regression test were applied to investigate publication bias.[@b21-ott-9-579]

Results
=======

Study selection and description
-------------------------------

A total of 27 eligible studies including 8,539 cases and 10,750 controls met the inclusion criteria. The HWE test was performed to determine the genotype distribution of the controls in all studies included. All of the studies, except for three,[@b22-ott-9-579]--[@b24-ott-9-579] were not in HWE, and two studies[@b25-ott-9-579],[@b26-ott-9-579] lacked sufficient data for calculating the *P*-value to determine HWE.

Quantitative data synthesis
---------------------------

The study characteristics are summarized in [Table 1](#t1-ott-9-579){ref-type="table"}. The genotype distribution and risk allele frequency of the included studies are summarized in [Table 2](#t2-ott-9-579){ref-type="table"}. Overall, there was no significant correlation between the XRCC1 Arg399Gln polymorphism and bladder cancer risk for A allele vs G allele (OR =0.87, 95% CI =0.71--1.06, *P*=0.160 for heterogeneity, [Figure 1A](#f1-ott-9-579){ref-type="fig"}), the codominant model AA vs GG (OR =1.01, 95% CI =0.81--1.26, *P*=0.959 for heterogeneity, [Figure 1B](#f1-ott-9-579){ref-type="fig"}), the dominant model AA/AG vs GG (OR =0.93, 95% CI =0.85--1.02, *P*=0.134 for heterogeneity, [Figure 1C](#f1-ott-9-579){ref-type="fig"}), and the recessive model AA vs AG/GG (OR =1.01, 95% CI =0.88--1.15, *P*=0.934 for heterogeneity, [Figure 1D](#f1-ott-9-579){ref-type="fig"}), but a moderately significant association was found for AG vs GG (OR =0.241, 95% CI =0.17--0.35, *P*=0.000 for heterogeneity, [Figure 2](#f2-ott-9-579){ref-type="fig"}). In subgroup analysis by ethnicity, no significant association was found between XRCC1 Arg399Gln polymorphism and bladder cancer risk among Asians (*P*\>0.05).

Sensitivity analysis
--------------------

The analysis of sensitivity was examined by sequential omission of individual studies. The significance of the pooled ORs in all individual and subgroup analyses was not excessively influenced by omitting any single study.

Heterogeneity and publication bias
----------------------------------

Heterogeneity among studies was found in all comparisons of the XRCC1 Arg399Gln polymorphism. Therefore, the random effects model was used for single studies in the subgroup analysis to minimize the impact of bias. Funnel plots demonstrated evidence of obvious asymmetry ([Figure 3](#f3-ott-9-579){ref-type="fig"}). Egger's test displayed strong statistical evidence of publication bias.

Discussion
==========

Few studies have been conducted to investigate the association between the XRCC1 Arg399Gln polymorphism and bladder cancer risk in recent decades. Compared with those who had the Arg/Arg genotype, a slight decrease was found in risk for individuals who carried the Gln/Gln genotype.[@b27-ott-9-579] Subsequently, a case-control investigation was carried out in Northern Italy, and the XRCC1 Arg399Gln polymorphism showed a protective effect on bladder cancer risk among heavy smokers.[@b28-ott-9-579] In comparison with Gln allele vs Arg allele, (Gln/Gln + Gln/Arg) vs Arg/Arg, Gln/Gln vs (Gln/Arg + Arg/Arg), Gln/Gln vs Arg/Arg, and Gln/Arg vs Arg/Arg, our meta-analysis based on these 27 studies revealed no correlation between the XRCC1 Arg399Gln polymorphism and bladder cancer risk.

As we know, mutations occurring in the nucleotide bases is the most common type of DNA damage, and they exhibit a high frequency (up to several thousand a day). Consequently, once the XRCC1 protein is lost, it may cause increased cell sensitivity to radiation, oxidative stress, and alkylating agents (eg, camptothecin).[@b14-ott-9-579] To date, more than 300 single nucleotide changes have been identified in the *XRCC1* gene.[@b29-ott-9-579] The Arg399Gln mutation leads to conformational changes in the XRCC1 protein that reduces its affinity for the multi-component DNA repair protein complex.[@b29-ott-9-579]

Presently, relationships between the XRCC1 Arg399Gln polymorphism and cancer development have been observed in several cancers. As previously reported, the alterations of XRCC1 are the most widely accepted suggestion to play a role in the pathogenesis of cancers.[@b30-ott-9-579],[@b31-ott-9-579] In particular, it has been found that the XRCC1 399Gln/Gln genotype was associated with lung cancer risk, as well as breast cancer risk in African Americans.[@b32-ott-9-579] However, no relationship between the XRCC1 Arg399Gln polymorphism and bladder cancer has been found in recent studies.

Notably, several limitations of our meta-analysis should be mentioned. Firstly, we strictly compiled data according to the rules of HWE, and ruled out three studies that might have caused the overall effects in our meta-analysis. Secondly, our systematic review was based on unadjusted data. Furthermore, the genotype information stratified for the main confounding variables was not available in the original papers.

Taken together, we have shown that there is no association between the XRCC1 Arg-399Gln polymorphism and bladder cancer risk. Additional large-scale studies with adequate methodological quality and controls for possible confounding effects should be conducted.
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###### 

Odds ratios for associations between single nucleotide polymorphism Arg399Gln in XRCC1 and bladder cancer risk.

**Notes:** (**A**) A allele vs G allele; (**B**) AA vs GG; (**C**) AA + AG vs GG; (**D**) AA vs AG + GG. Weights are from random effects analysis.

**Abbreviations:** OR, odds ratio; CI, confidence interval.
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![Forest plot of XRCC1 Arg399Gln AG genotypes versus the GG genotype.\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](ott-9-579Fig2){#f2-ott-9-579}

![Funnel plot of two single nucleotide polymorphisms Arg399Gln in XRCC1 and bladder cancer risk.\
**Note:** Begg's funnel plot with pseudo 95% confidence limits.\
**Abbreviations:** OR, odds ratio; SE, standard error.](ott-9-579Fig3){#f3-ott-9-579}

###### 

Baseline characteristics of studies included in the meta-analysis

  Study                                     Year   Country                      Method         Number of subjects   
  ----------------------------------------- ------ ---------------------------- -------------- -------------------- -------
  Akhmadishina LZ et al[@b33-ott-9-579]     2014   Russian                      PCR-RFLP       289                  173
  Chien-I Chiang CI et al[@b34-ott-9-579]   2014   People's Republic of China   PCR-RFLP       324                  647
  Volha P et al[@b35-ott-9-579]             2014   Belarus                      PCR-RFLP       332                  364
  Zhi Y et al[@b36-ott-9-579]               2012   People's Republic of China   PCR-RFLP       302                  311
  Mittal RD et al[@b37-ott-9-579]           2012   India                        ARMS PCR       212                  250
  Gao W et al[@b38-ott-9-579]               2012   USA                          PCR+SSCP       192                  313
  Wang M et al[@b39-ott-9-579]              2010   People's Republic of China   PCR-RFLP       234                  253
  Wen H et al[@b26-ott-9-579]               2009   People's Republic of China   TaqMan assay   80                   291
  Mittal RD et al[@b40-ott-9-579]           2008   India                        PCR-RFLP       140                  90
  Fontana L et al[@b41-ott-9-579]           2008   France                       TaqMan assay   51                   45
  Covolo L et al[@b42-ott-9-579]            2008   Italy                        PCR-RFLP       197                  211
  Arizono K et al[@b43-ott-9-579]           2008   Japan                        PCR-RFLP       251                  251
  Andrew AS et al[@b23-ott-9-579]           2008   USA                          PCR-RFLP       990                  1,253
  Sak SC et al[@b44-ott-9-579]              2007   UK                           TaqMan assay   532                  560
  Huang M et al[@b25-ott-9-579]             2007   USA                          TaqMan assay   613                  696
  Figueroa JD et al[@b45-ott-9-579]         2007   USA                          TaqMan assay   1,061                996
  Karahalil B et al[@b46-ott-9-579]         2006   Turkey                       PCR-RFLP       100                  100
  Andrew AS et al[@b47-ott-9-579]           2006   USA                          PCR-RFLP       306                  538
  Matullo G et al[@b31-ott-9-579]           2006   Italy                        PCR-RFLP       124                  1,094
  Wu X et al[@b48-ott-9-579]                2006   USA                          TaqMan assay   613                  596
  Matullo G et al[@b49-ott-9-579]           2005   UK                           PCR-RFLP       311                  312
  Broberg K et al[@b50-ott-9-579]           2005   Sweden                       Mass assay     61                   155
  Kelsey KT et al[@b24-ott-9-579]           2004   USA                          PCR-RFLP       355                  544
  Sanyal S et al[@b51-ott-9-579]            2004   Sweden                       PCR-RFLP       311                  246
  Shen M et al[@b28-ott-9-579]              2003   France                       PCR-RFLP       201                  214
  Matullo G et al[@b52-ott-9-579]           2001   Italy                        PCR-RFLP       124                  37
  Stern MC et al[@b27-ott-9-579]            2001   USA                          PCR-RFLP       233                  210

**Abbreviations:** PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; AMRS PCR, amplification refractory mutation system polymerase chain reaction; PCR+SSCP, polymerase chain reaction and single-strand conformation polymorphism.

###### 

Genotype distribution and risk allele frequency in all studies included

  Study (year)                              Case   Control   HWE test                             
  ----------------------------------------- ------ --------- ---------- ----- ----- ----- ------- -------
  Akhmadishina LZ et al[@b33-ott-9-579]     86     143       60         60    88    25    0.639   0.424
  Chien-I Chiang CI et al[@b34-ott-9-579]   179    108       37         350   253   44    0.036   0.850
  Volha P et al[@b35-ott-9-579]             141    154       37         151   165   48    0.076   0.782
  Zhi Y et al[@b36-ott-9-579]               121    151       30         148   143   20    3.571   0.588
  Mittal RD et al[@b37-ott-9-579]           67     106       39         102   109   39    1.186   0.276
  Gao W et al[@b38-ott-9-579]               85     107       --         136   177   --    --      --
  Wang M et al[@b39-ott-9-579]              113    102       19         105   126   22    3.414   0.065
  Wen H et al[@b26-ott-9-579]               46     34        --         153   138   --    --      --
  Mittal RD et al[@b40-ott-9-579]           37     76        27         73    81    36    2.459   0.117
  Fontana L et al[@b41-ott-9-579]           21     25        5          18    18    9     1.25    0.264
  Covolo L et al[@b42-ott-9-579]            92     105       --         91    120   --    --      --
  Arizono K et al[@b43-ott-9-579]           139    102       10         140   90    21    1.410   0.235
  Andrew AS et al[@b23-ott-9-579]           412    456       122        533   536   184   6.586   0.010
  Sak SC et al[@b44-ott-9-579]              218    248       66         226   259   75    0.003   0.953
  Huang M et al[@b25-ott-9-579]             266    347       --         367   329   --    --      --
  Figueroa JD et al[@b45-ott-9-579]         434    494       133        433   453   110   0.273   0.602
  Karahalil B et al[@b46-ott-9-579]         49     38        13         41    42    17    1.181   0.277
  Andrew AS et al[@b47-ott-9-579]           118    155       33         225   227   86    4.935   0.026
  Matullo G et al[@b31-ott-9-579]           54     53        17         484   482   128   0.229   0.632
  Wu X et al[@b48-ott-9-579]                266    277       70         267   256   73    0.913   0.339
  Matullo G et al[@b49-ott-9-579]           136    135       40         120   145   47    0.087   0.768
  Broberg K et al[@b50-ott-9-579]           26     31        4          80    62    13    0.041   0.840
  Kelsey KT et al[@b24-ott-9-579]           132    187       36         228   230   86    4.663   0.031
  Sanyal S et al[@b51-ott-9-579]            124    155       32         113   110   23    0.260   0.610
  Shen M et al[@b28-ott-9-579]              93     87        21         92    98    24    0.168   0.682
  Matullo G et al[@b52-ott-9-579]           53     58        13         12    19    6     0.111   0.739
  Stern MC et al[@b27-ott-9-579]            96     116       21         88    96    26    0.000   0.982

**Abbreviation:** HWE, Hardy-Weinberg equilibrium.
